Contract Pharma Manufacturing News
-
Naobios And Sumagen Sign Exclusive Partnership To Develop HIV Vaccine
4/15/2024
Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of virus-based products, today announces the signing of a partnership with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its phase II clinical trials. Financial terms were not disclosed.
-
Arvinas Enters Into A Transaction With Novartis, Including A Global License Agreement For The Development And Commercialization Of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 For The Treatment Of Prostate Cancer
4/11/2024
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer.
-
FUJIFILM Diosynth Invests $1.2B In Holly Springs, North Carolina, Manufacturing Facility, Creating 680 New Jobs
4/11/2024
FUJIFILM Diosynth Biotechnologies North Carolina, Inc., a world-leading contract development and manufacturing organization (CDMO), will invest $1.2 billion to expand its biopharmaceutical manufacturing facility in Holly Springs, North Carolina, creating 680 new jobs in Wake County.
-
NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement To Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials
4/10/2024
NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the signing of a Clinical Supply Agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials.
-
Asahi Kasei Bioprocess And Axolabs Announce Strategic Partnership To Accelerate Oligonucleotide Therapeutics Development
4/10/2024
Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics.
-
Sen-Jam Pharmaceutical Partners With Specialty Pharmaceutical Manufacturer To Provide Formulation And Chemistry, Manufacturing & Controls For Revolutionary Anti-Inflammatory Injectable
4/10/2024
Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel uses, has entered a third strategic partnership with KVK-Tech. KVK-Tech is a leading Specialty Pharmaceutical Manufacturing company that will be providing formulation and Chemistry, Manufacturing & Controls (CMC) for Sen-Jam's first injectable anti-inflammatory therapeutic, SJP-100.
-
Ascend Acquires GMP Manufacturing Capacity In Alachua, Florida; Enters Long-Term Partnership With Beacon Therapeutics For Clinical And Commercial AAV Production
4/9/2024
Ascend Advanced Therapies (Ascend), a total solutions gene therapy development partner, has acquired the CMC team and site in Alachua, Florida from Beacon Therapeutics (Beacon). The transaction brings an operational good manufacturing practice (GMP) facility, process and analytical development capabilities, and additional experts to the Ascend team. It also includes a long-term partnership with Beacon to continue manufacturing its products for clinical and commercial use, securing product supply for Beacon and enabling it to focus on clinical development.
-
Virtuosi Becomes An IACET Accredited Provider
4/9/2024
The International Accreditors for Continuing Education and Training (IACET) has awarded Virtuosi the prestigious Accredited Provider accreditation.
-
Kindeva Drug Delivery And Syntegon Install First Versynta Microbatch In North America
4/9/2024
Syntegon today announced the sale of its newly developed Versynta microBatch production cell to its first U.S. customer. Kindeva Drug Delivery will use Versynta microBatch to further expand its suite of aseptic fill-finish contract development and manufacturing (CDMO) capabilities meeting the latest global pharmaceutical regulations and trends.
-
NeuroSense Collaborates With Lonza To Identify Exosome-Based Biomarkers, In Order To Advance Neurodegenerative Disease Treatments And Diagnostics
4/9/2024
Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases, announced a collaboration to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS.